Skip to main content

Table 1 Characteristics of the 4,488 enrolled critically ill patients divided by overall mortality

From: Culture positivity may correlate with long-term mortality in critically ill patients

 

All

Non-survivors

Survivors

p value

(N = 4488)

(N = 2477)

(N = 2011)

Basic characteristics

 Age, years

66.4 ± 16.4

69.7 ± 15.5

62.3 ± 16.6

< 0.01

 Sex (male)

2866 (63.9%)

1634 (66.0%)

1232(61.3%)

< 0.01

 Body mass index

24.4 ± 4.7

23.9 ± 4.7

24.9 ± 4.7

< 0.01

 Charlson comorbidity index

2.4 ± 1.6

2.7 ± 1.6

2.0 ± 1.5

< 0.01

 Immunocompromised patients

953 (21.2%)

578 (23.3%)

375(18.7%)

< 0.01

 Malignancy, active

601 (13.4%)

508 (20.5%)

93 (4.6%)

< 0.01

 Solid tumor, active

427 (9.5%)

372 (15.0%)

55 (2.7%)

< 0.01

 Hematological malignancy

174 (3.9%)

136 (5.5%)

38 (1.9%)

< 0.01

 Autoimmune diseases

107 (2.4%)

54 (2.2%)

53 (2.6%)

0.32

 Organ transplant recipients

15 (0.3%)

7 (0.3%)

8 (0.4%)

0.51

 Follow-up duration, years

1.2 ± 1.3

0.4 ± 0.8

2.2 ± 1.3

< 0.01

Etiology for ICU admission

 Sepsis with acute respiratory failure

2584 (57.6%)

1668 (67.3%)

916 (45.5%)

< 0.01

 Acute neurological conditions

431 (10.6%)

170 (7.0%)

261 (13.0%)

 Acute cardiac conditions

190 (4.2%)

42 (1.7%)

148 (7.4%)

 Acute gastrointestinal condition

174 (3.9%)

109 (4.4%)

65 (3.2%)

 Acute renal conditions

121 (2.7%)

56 (2.3%)

65 (3.2%)

 Major surgery

101 (2.3%)

35 (1.4%)

66 (3.3%)

 Cardiac arrest

25 (0.6%)

22 (0.9%)

3 (0.2%)

 Others

862 (19.2%)

375 (15.1%)

487 (24.2%)

Severity and managements

 APACHE II score

25.1 ± 7.5

27.7 ± 7.0

21.9 ± 6.7

< 0.01

 Presence of shock

2068 (46.1%)

1476 (59.6%)

592 (29.4%)

< 0.01

 Receiving mechanical ventilation

3295 (73.4%)

2044 (82.5%)

1,251 (62.2%)

< 0.01

Renal replacement therapy (RRT)

 Temporal RRT during admission

708 (15.8%)

533 (21.5%)

175 (8.7%)

< 0.01

 RRT for ESRD

125 (2.8%)

68 (2.8%)

57 (2.8%)

0.86

 Fluid balance, day 1–3, mL

717.6 ± 3727.4

1408.7 ± 4106.1

− 133.6 ± 2988.9

< 0.01

Microbiologic data

 Positive culture, any culture site

2362 (52.6%)

1608 (64.9%)

754 (37.5%)

< 0.01

 Blood

631 (14.1%)

491 (19.8%)

140 (7.0%)

< 0.01

 Respiratory Tract

1823 (40.6%)

1267(51.2%)

556 (27.7%)

< 0.01

 Urinary Tract

831 (18.5%)

607 (24.5%)

224 (11.1%)

< 0.01

 Other sites

160 (3.6%)

111 (4.5%)

49 (2.4%)

< 0.01

 Positive MDRO1

1286 (28.7%)

925 (37.3%)

361 (18.0%)

< 0.01

Outcomes

 ICU-stay, days

9.9 ± 8.4

11.3 ± 8.8

8.3 ± 7.6

< 0.01

 Hospital-stay, days

24.2 ± 19.1

26.4 ± 19.7

21.6 ± 17.8

< 0.01

 Ventilator-day

9.8 ± 9.1

10.8 ± 9.6

8.1 ± 8.0

< 0.01

Mortality at distinct time points

 In-hospital mortality

1260 (28.1%)

1260 (50.9%)

NA

NA

 90-day mortality

1707 (38.0%)

1707 (68.9%)

NA

NA

 1-year mortality

2117 (47.2%)

2117 (85.5%)

NA

NA

  1. 1MDRO, included methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and carbapenem-resistant Gram-negative bacilli. APACHE II acute physiology and chronic health evaluation, RRT renal replacement therapy, ESRD end-stage renal disease, MDRO multidrug-resistant organism, ICU intensive care unit, NA not applicable